drugset / Trial / NCT00849797
Oxcarbazepine 600 mg Tablets Under Non-Fasting Conditions
RandomizedCrossoverOpen-labelOther
Summary
The objective of this study is to compare the rate and extent of absorption of a test formulation of oxcarbazepine tablets and Trileptal® tablets administered as a 1 x 600 mg dose under fed conditions.
Timeline
- Start
- 2005-07
- Primary completion
- 2005-07
- Completion
- 2005-07
Outcome
Met primary endpoint
registry Test/Ref Ratio of LS Means x 100 90.86 (90% CI 85.47 to 96.60) NCT00849797 ↗
registry Test/Ref Ratio of LS Means x 100 98.60 (90% CI 96.59 to 100.66) NCT00849797 ↗
registry Test/Ref Ratio of LS Means x 100 98.74 (90% CI 96.71 to 100.80) NCT00849797 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxcarbazepine | Small molecule | 600 mg | — |
Indications
No indication recorded.